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 Prostate cancer (PCa) is one of the most common cancers and 
the second leading cause of cancer death in men.  Regarding that 
prostate cancer is the most common form of cancer in men and is 
the second leading cause of cancer mortality, paclitaxel, as a 
chemotherapeutic agent with a wide spectrum of antitumor 
activity, could be utilized in treatment of this malignancy. 
Paclitaxel side effects are severe hypersensitivity reactions, 
neurotoxicity, and nephrotoxicity. Today’s decline of side effects 
and increase in efficacy of chemotherapeutic agents by applying 
nanotechnology in medicine is the target of scientists. Niosomes 
or nonionic surfactant vesicles are nano vehicles utilized in drug 
delivery systems. Niosomes are prepared by various methods. 
Our present work investigated the efficiency of encapsulation of 
paclitaxel in noisome (Nio-PTX) as a novel vesicular drug 
delivery system and cytotoxic effects on PC-3 prostate cancer cell 
line. In this study, paclitaxel loaded niosome was prepared by 
thin film hydration method. The characterization tests that 
included dynamic light scattering (DLS) and UV-Vis 
spectrophotometry were employed to evaluate the quality of the 
nanocarriers. Percent of encapsulation paclitaxel prepared with 
sorbitane monostearate and cholesterol was 99.4%. In addition, 
the polydispersity index, mean size diameter and zeta potentials 
of niosomal paclitaxel nanoparticles were found to be 0.203 ± 
0.012, 119.7 ± 2.5 nm and -4 ± 0.34, respectively. Cytotoxicity of 
niosomal paclitaxel nanoparticles and free paclitaxel on human 
prostate cancer cell line PC-3 after 24 hours were studied by 
MTT assay to determine cell viability. The results demonstrated 
that a 1.5∼fold reduction in paclitaxel concentration was 
measured when the paclitaxel administered in nanoniosome 
compared to free paclitaxel solution in PC3 human prostate 
cancer cell line. As a result, the nanoparticle-based formulation of 
paclitaxel has high potential as an adjuvant therapy for clinical 
usage in human prostate cancer therapy 
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  Cancer is one of the main causes of mortality worldwide and demonstrates a serious health 
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problem (1). By 2050, according to the World 
Health Organization (WHO), it is anticipated that 
17.5 million cancer deaths and 27 million new 
cancer cases will happen annually (2). The prostate 
is below the bladder and in front of the rectum. The 
size of the prostate changes with age. In younger 
men, it is about the size of a walnut, but it can be 
much larger in older men (3). Prostate cancer is the 
development of cancer in the prostate. Prostate 
cancers are slow growing; however, some grow 
relatively quickly. The cancer cells may spread 
from the prostate to other region of the body, 
particularly the bones and lymph nodes. It may 
initially cause no symptoms. In later stages it can 
lead to difficulty urinating, blood in the urine, or 
pain in the pelvis, back or when urinating (4, 5). 
Older age, a family history of the disease, and race 
are factors that increase the risk of prostate cancer 
(6, 7). Prostate-specific antigen (PSA) blood test, a 
digital rectal exam (DRE) and finally a prostate 
biopsy are the main methods of diagnosis of 
prostate cancer (5). Prostate cancer is the most 
frequently diagnosed non-cutaneous neoplasm in 
and the second leading cause of cancer-related 
mortality in men (8, 9). Prostate cancer is 
frequently diagnosed in men between 45 and 89 
years of age (10). It is a major cause of morbidity 
and mortality in Iran. Prostate cancer is becoming 
an increasingly important public health problem, 
particularly in countries with  trends toward an 
aging  population (11).  Routine screening, early 
diagnosis, newer treatment options, and the 
possibility of cure have increased prostate cancer 
survivorship impressively. Paclitaxel (PTX) is a 
diterpenoid natural plant product (western yew, 
Taxus brevifolia) with a unique antineoplastic 
mechanism of action.  PTX has been utilized for 
many years to treat ovarian, breast, lung, bladder, 
prostate, esophageal, pancreatic cancer, metastatic 
melanoma and leukemia. PTX is a cell cycle-
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-speciﬁc drug that bind with high-afﬁnity to 
microtubules, stabilizing and enhancing tubulin 
polymerization and suppressing spindle 
microtubule dynamics. Therefore, paclitaxel   
effectively inhibits mitosis, motility and 
intracellular transport within cancerous cells, 
leading to apoptotic cell death (12-17). The clinical 
advances of paclitaxel has been limited by its 
chemical formulation due to its low solubility, 
paclitaxel is formulated in a mixture of Cremophor 
EL/absolute ethanol (1:1 v/v). Cremophor EL is 
known to cause severe hypersensitivity reactions, 
myelosuppression, and peripheral neuropathy. As a 
result, various formulation strategies have been 
investigated to reduce vehicle-related side effects 
and meanwhile improve the chemotherapeutic 
efficacy of PTX (18-20). Significantly, much 
interest has been concentrated on developing 
nanotechnology-based PTX formulation such as 
polymeric micelles, liposomes, solid lipid 
nanoparticles, PTX-polymer conjugates and 
emulsions (21-25). Nanotechnology has 
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revolutionized diagnosis and treatment of cancer 
(26). Nano-sized drug delivery system (DDS), or 
Nano carrier, is designed to deliver therapeutic and/
or diagnostic agents to their target sites (27). Over 
the last decades, drug delivery systems using 
vesicular carriers have attracted great interest 
because these carriers provide high encapsulation 
efficiency, control drug release, enhance drug 
solubility, carry both hydrophilic and hydrophobic 
drugs, reduce side effects, prolong circulation in 
blood and ability to target a specific area (28, 29). 
By definition, vesicles made of natural or synthetic 
phospholipids are called liposomes while 
transferosomes are modified liposomal systems 
that, in addition to phospholipids, contain a single 
chain surfactant as an edge activator. Ethosomes 
contain ethanol as an edge activator instead of a 
single chain surfactant. Despite having some 
advantages over conventional dosage forms, they 
have found many problems in practical applications 
such as high cost, utilize of organic solvent for 
preparation and limited shelf life due to the lipids 
rancidification (30). Therefore, continuous 
endeavor is concentrated on finding an alternative 
vesicular carrier that is capable to provide adequate 
stability, biocompatibility and lower toxicity. This 
requirement is accomplished  by niosomes and they 
are emerging as an noteworthy candidate for drug 
delivery applications (31). Niosomes or non-ionic 
surfactant vesicles are uni- or multilamellar 
spheroidal structures. Niosomes are preferred as an 
effective alternative to conventional liposomes. 
They offer several advantages over liposome such 
as greater stability, lower cost, biodegradable, 
biocompatible, non-immunogenic, low toxicity and 
lesser care in storage for industrial production in 
pharmaceutical applications. The niosomal systems 
are considered to enhance the bioavailability of 
poorly water-soluble drugs such as paclitaxel (29,  
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32-36). The present study seeks to effectively 
deliver paclitaxel to PC-3 human prostate cancer 
cell line using niosomes in order to improve the 
solubility and the therapeutic effects of paclitaxel. 
Materials and Methods 
Preparation of paclitaxel niosome by the thin 
film hydration method  
The thin film hydration method employed to 
prepare niosome (37). Surfactant of sorbitane 
monostearate (Span 60) (Sigma Chemical Co St 
Louis, MO, USA) and cholesterol (Sigma, USA) 
(90:10 molar ratios) were dissolved in chloroform. 
Then 0.5 mg.mL-1 paclitaxel (Stragen, Switzerland) 
was added and the mixture was warmed to 45 ºC 
for 30 min .The solvent phase was evaporated on 
rotary evaporator until a thin-layered film formed. 
The thin film was hydrated with 3000µl distilled 
water at 55 ºC for 45 min. The resultant 
suspensions were sonicated (model UP200St, 
Hielscher Ultrasonics GmbH, Germany) at 50 HTz 
and 4 ºC for 45 min in order to decrease niosomal 
particle size. Afterwards, free PTX (unloaded) was 
separated from niosomal PTX (Nio-PTX) by 
dialysis membrane (Jingkehongda Biotechnology 
Co., Ltd Beijing, China) that had a cut-off of 12 
kDa. 
Size and polydispersity index determination of 
nanoparticles  
The  particle  size  distribution  and  polydispersity  
index  (PDI)  of  the  niosome  particles  was 
determined by dynamic light scattering  (DLS) using 
a ZetaPALS zeta potential and particle size analyzer 
(Brookhaven Instruments, Holtsville, NY, USA).  
 Analysis of encapsulation efficiency 
In order to evaluate the entrapment eﬃciency, 
spectroscopic measurements were performed. The 
Nio-PTX particles were lysed with isopropanol to 
analyze PTX concentration. The amounts of PTX in 
niosome formulation were analyzed with a UV 
spectrophotometer (model T80+, PG Instruments, 
United Kingdom) at 236 nm (ʎmax) (31). 
Cell lines and culture conditions 
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PC-3 human prostate cancer cell line (obtained 
from the Iranian Biological Resource 
Center ,Tehran, Iran) was  cultured  in DMEM 
medium  supplemented with 10% fetal bovine 
serum (FBS), and penicillin/streptomycin (1 mg/
mL) at  37°C  and  5%  CO2  in  a  humidified  
incubator 
Cytotoxicity assays 
The cytotoxicity of niosomal formulations was 
determined by the MTT assay (38, 39). Briefly, PC-
3 cells were seeded in 96-well plates at 2×104 cells 
per well. Following attachment 24 hours, the cells 
were treated with 200 μl fresh medium containing 
serial dilutions of free-PTX solution and niosomal 
PTX. After incubation for 24 h, 10 μl MTT (5 
mg.ml-1 in PBS) was added into each 96- well plate 
and incubated for three hour at 37 ˚C. Finally, the 
medium was carefully removed and 150 μl of 
DMSO was added to the each well to dissolve the 
formazan crystals formed. Absorbance of each well 
was recorded by EPOCH Microplate 
Spectrophotometer (synergy HTX, BioTek, USA) 
at 570 nm. The cytotoxicity of the diﬀerent 
formulations was expressed as the Inhibitory 
Concentration (IC50) value defined as the drug 
concentration required inhibiting cell growth by 
50% relative to the control. The IC50 values of free 
PTX and Nio-PTX were calculated using GraphPad 
Prism software. 
Statistical analysis 
Statistical data analyses were performed via 
GraphPad Prism software and expressed as mean ± 
SD. The student t-test was used when comparing 
two independent groups. P-Value < 0.05 was 
considered significant. 
Results 
Characterization of Niosome formulation  
The polydispersity index, mean size diameter and 
zeta potentials of niosomal paclitaxel nanoparticles 
prepared with sorbitane monostearate and 
cholesterol were found to be 0.203 ± 0.012, 119.7 ± 
2.5 nm and -4 ± 0.34, respectively. 
Encapsulation efficiency 
 Encapsulation efficiency of formulation was 
determined through paclitaxel standard curve in 
isopropanol (Fig. 1). Percent encapsulation of 
paclitaxel in niosome nanoparticles was determined 
to be 99.4± 0.8 % . 
Evaluation of cellular cytotoxicity effect 
It was observed that toxicity of paclitaxel in niosome 
formulation prepared with sorbitane monostearate 
and cholesterol was higher than toxicity of free 
paclitaxel. Furthermore, determined IC50 for 
niosome formulation was 17.09 μg/ml, while the 
IC50 for free drug was determined to be 25.4 μg/ml 
(Fig.2 and Fig.3, respectively). The results showed 
that the paclitaxel niosome formula displayed 
significantly greater cytotoxic activity with PC-3 
prostate cancer cell line in comparison free 
paclitaxel.  
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Fig. 1. Paclitaxel standard curve in isopropanol   
Fig. 2.  Cell viability assay of PC-3 cell line after 24 hours of treatment with various concentrations of niosomal paclitaxel 
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Fig. 3.  Cell viability assay of AGS cell line after 24 hours of treatment with various concentrations of free paclitaxel 
Discussion 
Drug delivery is one of the major challenges in 
pharmaceutical biotechnology. The most 
important problems in cancer therapy are 
inadequate concentration in drug delivery into 
target locations and reducing drug side effects on 
healthy cells. Nanoparticles have become very 
attractive for their functions in the fields of 
biology and medicine in recent years. 
Nanoparticles also assign a targeted direction to 
specific organs or cells or controlled drug delivery. 
The main objectives in designing nanoparticles as 
a delivery system are to manage surface 
properties, particle size and release of drugs, in 
order to obtain the site- specific action of the drug 
at the therapeutically optimal rate and dose 
regimen. Nanoparticle delivery systems are 
attractive as they target tumor cells and increase 
the tumor accumulation of anticancer drugs in 
tumor cells more than in healthy tissues. Lipid 
nanocarriers are biodegradable, biocompatible and 
are not toxic in vivo. Niosomes are one of the 
lipoid nanocarriers (40). Niosomes have several 
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advantages such as high patient compliance, 
accommodate drug molecules with a wide range 
of solubilities, variable and controllable 
characteristics, controlled drug release, increasing 
the stability of encapsulated drug, improving oral 
bioavailability of poorly absorbed agents, 
enhancing skin penetration of drugs and reaching 
the site of action by oral, parenteral and topical 
routes (34, 41, 42). Nonionic surfactants are the 
most common type of surfactant used in preparing 
vesicles due to the superior beneﬁts they impart 
with respect to stability, compatibility and toxicity 
compared to their anionic, amphoteric or cationic 
counterparts (43). Nanoparticles average 
diameter, size distribution and zeta potential 
obtained. The thin film hydration method used in 
this study to prepare niosomes is easy, appropriate 
encapsulation efficiency and low cost benefit. 
Measurement results in nanoniosomal paclitaxel 
affirmed the particle size in nano scale. In a 
research conducted by Zarei et al, niosomal 
paclitaxel was investigated as a drug delivery 
system that its results illustrated the size of 
nanoparticles was 284 nm (44). The results of 
studying encapsulation efficiency showed that 
amount of paclitaxel entrapped in nanoniosome 
formulation was very high. Sonication processes 
not only reduced the size of particles, but also 
caused particles to be more homogeneous by 
reducing the size distribution. The present study 
investigated the cytotoxicity effect of both 
nanoniosomal paclitaxel and free paclitaxel on PC
-3 cells. The findings demonstrated that 
encapsulated paclitaxel has more potency 
compared to the standard drug that was significant 
statistically. The increase of paclitaxel efficacy by 
liposomal nanoparticles reported by other 
investigators. Akbarzadeh et al prepared a 
PEGylated niosome containing paclitaxel and 
evaluated its cytotoxicity effects on MCF-7 cells. 
They found that pegylated niosome potentiates the 
paclitaxel cytotoxicity as compared to the 
standard drug (44). In addition, the Chiani et al.  
showed  that  the  cytotoxic  effects  of 
nanoliposomal paclitaxel  on  breast  cancer  cell  
line  are  more  compared  to  the  standard  drug 
(45). 
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Conclusion 
The thin film hydration method along with niosomal ingredients and molar ratios of materials was found to be 
proper for the preparation of paclitaxel loaded niosomal nanoparticles. The results of study affirmed the 
positive effect of sonication process to prepare the smaller particles. The results indicated that most of the drug 
is encapsulated into the carrier. In addition, niosomal nanoparticles could increase the cytotoxicity effects of 
paclitaxel on PC-3 human prostate cancer cell line. Findings of the study suggest that niosome is a suitable 
carrier for paclitaxel anticancer and finally drug nanoparticle-based formulation of paclitaxel has high potential 
as an adjuvant therapy for clinical usage in prostate cancer. 
 
